Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash & Current Investments (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Cash & Current Investments for 12 consecutive years, with $143.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Current Investments rose 22.14% year-over-year to $143.6 million, compared with a TTM value of $143.6 million through Sep 2025, up 22.14%, and an annual FY2024 reading of $100.6 million, down 42.34% over the prior year.
  • Cash & Current Investments was $143.6 million for Q3 2025 at CytomX Therapeutics, down from $158.1 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $393.8 million in Q1 2021 and bottomed at $79.9 million in Q1 2025.
  • Average Cash & Current Investments over 5 years is $195.9 million, with a median of $193.6 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments skyrocketed 58.84% in 2021, then tumbled 46.84% in 2025.
  • Year by year, Cash & Current Investments stood at $305.2 million in 2021, then tumbled by 36.56% to $193.6 million in 2022, then fell by 9.88% to $174.5 million in 2023, then crashed by 42.34% to $100.6 million in 2024, then surged by 42.74% to $143.6 million in 2025.
  • Business Quant data shows Cash & Current Investments for CTMX at $143.6 million in Q3 2025, $158.1 million in Q2 2025, and $79.9 million in Q1 2025.